← Back to Search

Rho Kinase Inhibitor

Eye Drops for Open-Angle Glaucoma

Phase 2
Waitlist Available
Research Sponsored by Alcon Research
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Stage 1: Diagnosis of OAG or OHT in both eyes
Stage 1: High unmedicated IOP measurements in the study eye as specified in the protocol
Must not have
Stage 1 and Stage 2: Current use of more than 2 ocular hypotensive medications within 30 days (either eye)
Stage 1 and Stage 2: Any abnormality preventing reliable measurements
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline (8:00, 10:00, 12:00, 16:00), day 1 (8:00, 10:00, 12:00), day 8 (8:00, 10:00, 12:00, 16:00)
Awards & highlights

Summary

"This trial aims to test the safety and effectiveness of two different eye drops in people with open-angle glaucoma or high eye pressure."

Who is the study for?
This trial is for individuals with open-angle glaucoma or ocular hypertension. Participants should have a specific level of eye pressure and vision capability, and be able to administer eye drops themselves or with help. Those who've had certain eye treatments or conditions that could affect the study's outcome can't join.
What is being tested?
The trial is testing the safety and effectiveness of two ophthalmic solutions: AR-17043 and PG043, in lowering eye pressure for patients with open-angle glaucoma or ocular hypertension. It compares these new treatments against other known medications like Netarsudil and Latanoprost.
What are the potential side effects?
Possible side effects may include discomfort in the eyes, redness, changes in vision, dryness, tearing, sensitivity to light, an allergic reaction at the application site, or potentially increased pigmentation around the eyes.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with open-angle glaucoma or high eye pressure in both eyes.
Select...
My eye pressure is high without medication, as defined in the study.
Select...
My vision in the study eye is at least 20/200.
Select...
I have been diagnosed with open-angle glaucoma or high eye pressure in both eyes.
Select...
My untreated eye pressure is high as per the study's criteria.
Select...
My vision in the study eye is at least 20/100.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am using more than 2 eye pressure-lowering medications.
Select...
I don't have any conditions that would prevent accurate medical measurements.
Select...
I struggle to put in eyedrops correctly.
Select...
My eye pressure is over 36 mmHg.
Select...
My glaucoma is not open-angle type and is in early stages.
Select...
I have had surgery for glaucoma.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 8 (8:00, 10:00, 16:00); day 15 (8:00, 10:00, 16:00); day 29 (8:00, 10:00, 16:00)
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 8 (8:00, 10:00, 16:00); day 15 (8:00, 10:00, 16:00); day 29 (8:00, 10:00, 16:00) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Mean diurnal IOP at Day 29 (Stage 2)
Mean diurnal IOP at Day 8 (Stage 1)
Secondary outcome measures
Mean IOP at each post-treatment timepoint (Stage 1)
Mean IOP at each post-treatment timepoint (Stage 2)
Mean change from baseline mean diurnal IOP at each post-treatment timepoint (Stage 1)
+7 more

Trial Design

10Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: PG043 low concentration (Stage 2)Experimental Treatment1 Intervention
PG043 Ophthalmic Solution, one drop in each eye in the evening on Days 1-28.
Group II: PG043 high concentration (Stage 2)Experimental Treatment1 Intervention
PG043 Ophthalmic Solution, one drop in each eye in the evening on Days 1-28.
Group III: AR-17043 medium concentration (Stage 1)Experimental Treatment1 Intervention
AR-17043 Ophthalmic Solution, one drop in each eye in the morning on Day 1, followed by one drop in each eye in the evening on Days 2-7.
Group IV: AR-17043 low concentration (Stage 1)Experimental Treatment1 Intervention
AR-17043 Ophthalmic Solution, one drop in each eye in the morning on Day 1, followed by one drop in each eye in the evening on Days 2-7.
Group V: AR-17043 high concentration (Stage 1)Experimental Treatment1 Intervention
AR-17043 Ophthalmic Solution, one drop in each eye in the morning on Day 1, followed by one drop in each eye in the evening on Days 2-7.
Group VI: Rhopressa (Stage 1)Active Control1 Intervention
Netarsudil 0.02% Ophthalmic Solution, one drop in each eye in the morning on Day 1, followed by one drop in each eye in the evening on Days 2-7.
Group VII: AR-17043 high concentration (Stage 2)Active Control1 Intervention
AR-17043 Ophthalmic Solution, one drop in each eye in the evening on Days 1-28.
Group VIII: Latanoprost (Stage 2)Active Control1 Intervention
Latanoprost 0.005% Ophthalmic Solution, one drop in each eye in the evening on Days 1-28.
Group IX: Rocklatan (Stage 2)Active Control1 Intervention
Netarsudil 0.02%/Latanoprost 0.005% Ophthalmic Solution, one drop in each eye in the evening on Days 1-28.
Group X: AR-17043 vehicle (Stage 1)Placebo Group1 Intervention
AR-17043 Vehicle, one drop in each eye in the morning on Day 1, followed by one drop in each eye in the evening on Days 2-7.

Find a Location

Who is running the clinical trial?

Alcon ResearchLead Sponsor
713 Previous Clinical Trials
125,374 Total Patients Enrolled
Clinical Trial Lead, PharmaStudy DirectorAlcon Research, LLC
~300 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top